The Influence of Lung Microbiota on Lung Carcinogenesis, Immunity, and Immunotherapy.
Adaptive Immunity
/ drug effects
Animals
Anti-Bacterial Agents
/ adverse effects
CTLA-4 Antigen
/ antagonists & inhibitors
Carcinogenesis
/ drug effects
Disease Models, Animal
Drug Resistance, Neoplasm
/ drug effects
Dysbiosis
/ complications
Host Microbial Interactions
/ drug effects
Humans
Immune Checkpoint Inhibitors
/ pharmacology
Immunity, Innate
/ drug effects
Inflammation
/ drug therapy
Intestinal Mucosa
/ immunology
Lung
/ immunology
Lung Neoplasms
/ drug therapy
Microbiota
/ drug effects
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Progression-Free Survival
Respiratory Mucosa
/ immunology
immunotherapy
lung carcinogenesis
lung microbiota
Journal
Trends in cancer
ISSN: 2405-8025
Titre abrégé: Trends Cancer
Pays: United States
ID NLM: 101665956
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
12
02
2019
accepted:
12
12
2019
entrez:
17
2
2020
pubmed:
18
2
2020
medline:
16
6
2021
Statut:
ppublish
Résumé
Microbiota have emerged as key modulators of both the carcinogenic process and the immune response against cancer cells, and, thus, it seems to influence the efficacy of immunotherapy. While most studies have focused on analyzing the influence of gut microbiota, its composition substantially differs from that in the lung. Here, we describe how microbial life in the lungs is associated with host immune status in the lungs and, thus, how the identification of the microbial populations in the lower respiratory tract rather than in the gut might be key to understanding the lung carcinogenic process and to predict the efficacy of different treatments. Understanding the influence of lung microbiota on host immunity may identify new therapeutic targets and help to design new immunotherapy approaches to treat lung cancer.
Identifiants
pubmed: 32061309
pii: S2405-8033(19)30265-1
doi: 10.1016/j.trecan.2019.12.007
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
CTLA-4 Antigen
0
Immune Checkpoint Inhibitors
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
86-97Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.